BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Maria-ferreira D, Dallazen JL, Corso CR, Nascimento AM, Cipriani TR, da Silva Watanabe P, de Mello Gonçales Sant'ana D, Baggio CH, de Paula Werner MF. Rhamnogalacturonan polysaccharide inhibits inflammation and oxidative stress and alleviates visceral pain. Journal of Functional Foods 2021;82:104483. [DOI: 10.1016/j.jff.2021.104483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu C, Zeng Y, Wen Y, Huang X, Liu Y. Natural Products Modulate Cell Apoptosis: A Promising Way for the Treatment of Ulcerative Colitis. Front Pharmacol 2022;13:806148. [DOI: 10.3389/fphar.2022.806148] [Reference Citation Analysis]
3 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Niu W, Yang F, Fu Z, Dong Y, Zhang Z, Ju J. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease. Microb Pathog 2021;:105381. [PMID: 34974123 DOI: 10.1016/j.micpath.2021.105381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu L, Liu Q, Chang J, Dong X, Ma W. Cell division control 42 elevates during infliximab therapy, and its increment relates to treatment response in ulcerative colitis patients. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24477] [Reference Citation Analysis]
6 Toychiev A, Navruzov B, Pazylova D, Davis N, Badalova N, Osipova S. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Acta Trop 2021;213:105755. [PMID: 33188747 DOI: 10.1016/j.actatropica.2020.105755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Quraishi MN, Shaheen W, Oo YH, Iqbal TH. Immunological Mechanisms Underpinning Faecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Clin Exp Immunol. 2019;199:24-38. [PMID: 31777058 DOI: 10.1111/cei.13397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
8 Chen W, He L, Zhong L, Sun J, Zhang L, Wei D, Wu C. Identification of Active Compounds and Mechanism of Huangtu Decoction for the Treatment of Ulcerative Colitis by Network Pharmacology Combined with Experimental Verification. Drug Des Devel Ther 2021;15:4125-40. [PMID: 34616145 DOI: 10.2147/DDDT.S328333] [Reference Citation Analysis]
9 Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Brookes MJ, Waller J, Cappelleri JC, Modesto I, DiBonaventura MD, Bohm N, Mokgokong R, Massey O, Wood R, Bargo D. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol 2020;7:e000456. [PMID: 32938582 DOI: 10.1136/bmjgast-2020-000456] [Reference Citation Analysis]
11 Dhillon P, Singh K. Therapeutic applications of probiotics in ulcerative colitis: An updated review. PharmaNutrition 2020;13:100194. [DOI: 10.1016/j.phanu.2020.100194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
12 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
13 Lu J, Zhou J, Wang L, Zhong C, Chen X, Jia B. Efficacy and safety evaluation of acupoint embedding for patients with ulcerative colitis: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21812. [PMID: 32846819 DOI: 10.1097/MD.0000000000021812] [Reference Citation Analysis]
14 Lu JJ, Maimaiti M, Liu H, Liu WD, Hui WJ, Huang XL, Gao F. Potential Biomarkers Associated with Differential Manifestations of Ulcerative Colitis (UC) in Uyghur and Han Population in China. J Inflamm Res 2021;14:7431-41. [PMID: 35002277 DOI: 10.2147/JIR.S335293] [Reference Citation Analysis]